The anti-melanogenesis effect of ligustroside derived from Ligustrum japonicum and its underlying mechanisms are explored.

Fintel reports that on March 26, 2025, Raymond James initiated coverage of Erasca (NasdaqGS:ERAS) with a Outperform ...

Results provide proof-of-concept that ERK pathway reactivation might be an effective, biologically based therapy to prevent anthrax-induced lethality.

Aberrant activation of the Ras/Raf/MAPK/ERK kinase/extracellular signal-regulated kinase cascade and the VEGF pathway are commonly observed in breast cancer cells leading to malignant cell ...

Presentations will feature potential best-in-class pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001Erasca will also present ...

data from the Company’s ongoing open-label dose escalation Phase 1 study in advanced cancer patients with MAPK pathway-driven ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...